Episode

Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo

Podcast: The Uromigos
Published: Feb 28, 2026
Duration seconds: 1887
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-485-ASCO-GU-2026---LITESPARK-011-LenBelzu-vs-Cabo-e3fk2k7
Audio: https://anchor.fm/s/13347ea8/podcast/play/116049991/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-25%2F418830529-44100-2-b7c309b2e3b3a.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo
Markdown: /podcast/the-uromigos-1214845/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-485-asco-gu-2026-litespark-011-len-belzu-vs-cabo.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.